Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $20,260.00 in Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) President Songjiang Ma sold 2,000 shares of the company's stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $10.13, for a total value of $20,260.00. Following the completion of the transaction, the president now directly owns 2,827,018 shares in the company, valued at approximately $28,637,692.34. This represents a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Songjiang Ma also recently made the following trade(s):

• On Monday, March 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.09, for a total transaction of $24,180.00.
• On Friday, March 14th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.31, for a total transaction of $24,620.00.
• On Wednesday, March 12th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.74, for a total transaction of $23,480.00.
• On Monday, March 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.14, for a total transaction of $20,280.00.
• On Friday, March 7th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.25, for a total value of $20,500.00.
• On Monday, February 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.90, for a total value of $23,800.00.
• On Tuesday, February 4th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.62, for a total value of $23,240.00.
• On Wednesday, January 29th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.43, for a total value of $22,860.00.
• On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.18, for a total transaction of $22,360.00.
• On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.49, for a total transaction of $20,980.00.

Gyre Therapeutics Stock Down 5.1 %

Shares of GYRE stock traded down $0.50 during trading hours on Monday, reaching $9.21. The company's stock had a trading volume of 293,567 shares, compared to its average volume of 82,195. Gyre Therapeutics, Inc. has a fifty-two week low of $8.26 and a fifty-two week high of $19.00. The company has a market capitalization of $862.17 million, a price-to-earnings ratio of 184.20 and a beta of 1.93. The firm's 50 day simple moving average is $11.29 and its 200-day simple moving average is $12.18.

Remove Ads

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last released its quarterly earnings data on Monday, March 17th. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.03). The business had revenue of $27.87 million during the quarter, compared to analyst estimates of $23.50 million. Gyre Therapeutics had a negative net margin of 84.57% and a negative return on equity of 118.43%.

Hedge Funds Weigh In On Gyre Therapeutics

A number of institutional investors have recently added to or reduced their stakes in GYRE. Charles Schwab Investment Management Inc. grew its stake in shares of Gyre Therapeutics by 392.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company's stock worth $1,425,000 after buying an additional 90,557 shares during the last quarter. Advantage Alpha Capital Partners LP acquired a new stake in shares of Gyre Therapeutics during the 3rd quarter valued at $334,000. FMR LLC bought a new stake in Gyre Therapeutics during the 3rd quarter worth $47,000. State Street Corp increased its holdings in Gyre Therapeutics by 8.8% in the 3rd quarter. State Street Corp now owns 104,490 shares of the company's stock worth $1,310,000 after purchasing an additional 8,412 shares in the last quarter. Finally, Barclays PLC raised its position in Gyre Therapeutics by 281.8% in the third quarter. Barclays PLC now owns 9,288 shares of the company's stock valued at $116,000 after purchasing an additional 6,855 shares during the last quarter. 23.99% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Noble Financial assumed coverage on shares of Gyre Therapeutics in a research report on Tuesday, March 11th. They set an "outperform" rating on the stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.